Europe greenlights first human genetic modifications

In a European first, Crispr Therapeutics (CRISPR is a gene editing technology) will begin human trials of a gene-splicing treatment for beta thalassaemia, a blood disorder that reduces the production of haemoglobin, which carries oxygen to cells.

This is a Biznews Premium article. Please login or sign up for a free 1-month trial.